1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
ClearPoint Neuro, Inc.

ClearPoint Neuro, Inc.

CLPT
ClearPoint Neuro, Inc.US flagNASDAQ Capital Market
12.37
USD
-0.27
- -
370.97MMarket Cap

Total Valuation

ClearPoint Neuro, Inc. carries a market capitalization of 370.97M, placing it among publicly traded companies globally. Its enterprise value stands at 289.57M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap370.97M
Enterprise Value289.57M

Share Statistics

ClearPoint Neuro, Inc. currently has 29.99M shares outstanding.

Shares Outstanding29.99M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 6.44, and the price-to-book ratio stands at -1.16.

PE RatioN/A
PS Ratio6.44
PB Ratio-1.16
P/TBV Ratio-127.60
P/FCF Ratio-10.57
P/OCF Ratio-10.17

Enterprise Valuation

EV / Sales7.13
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

ClearPoint Neuro, Inc. maintains a current ratio of 5.79, meaning it holds 5.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 337.50, indicating elevated leverage, while an interest coverage ratio of -5.98 demonstrates limited ability to service its debt obligations.

Current Ratio5.79
Quick Ratio4.67
Debt / Equity337.50
Debt / EBITDA-2.71
Interest Coverage-5.98

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-47.08
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.02

Taxes

Income Tax45,000.00
Effective Tax RateN/A

Stock Price Statistics

ClearPoint Neuro, Inc.'s stock has declined approximately -2.29068% over the past 52 weeks. The 50-day moving average sits at 10.84, while the 200-day moving average is 14.15.

Beta (5Y)N/A
52-Week Price Change-2.29068%
50-Day Moving Average10.84
200-Day Moving Average14.15
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, ClearPoint Neuro, Inc. generated 40.61M in revenue and converted that into -29.07M in net income, yielding earnings per share of -1.01. EBITDA reached -23.46M, while operating income came in at -26.48M.

Revenue40.61M
Gross Profit25.32M
Operating Income-26.48M
Pretax Income-29.02M
Net Income-29.07M
EBITDA-23.46M
EBIT-26.48M
Earnings Per Share (EPS)-1.01

Balance Sheet

ClearPoint Neuro, Inc. holds 35.59M in cash and equivalents against 63.59M in total debt, resulting in a net debt position of 14.05M. Total book value stands at -226.16M, with working capital of 45.40M providing operational flexibility.

Cash & Cash Equivalents35.59M
Total Debt63.59M
Net Debt14.05M
Equity (Book Value)-226.16M
Book Value Per Share-7.87
Working Capital45.40M

Cash Flow

ClearPoint Neuro, Inc. produced -25.72M in operating cash flow over the past twelve months. After subtracting -984,000.00 in capital expenditures, free cash flow totaled -26.70M - equivalent to -0.93 per share.

Operating Cash Flow-25.72M
Capital Expenditures-984,000.00
Free Cash Flow-26.70M
FCF Per Share-0.93

Margins

ClearPoint Neuro, Inc. operates with a gross margin of 62.33, reflecting its pricing power and cost economics. The operating margin of -65.20 and net profit margin of -71.57 provide insight into operational efficiency.

Gross Margin62.33
Operating Margin-65.20
Pretax Margin-71.46
Profit Margin-71.57
EBITDA Margin-57.77

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-19.00
FCF Yield-9.46

Stock Splits

ClearPoint Neuro, Inc.'s most recent stock split took place on July 27, 2016 with a 40:1 split ratio.

Last Split Date7/27/2016
Split Ratio40:1

Scores

ClearPoint Neuro, Inc. posts an Altman Z-Score of -2.16, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-2.16